FIELD: pharmacology.
SUBSTANCE: group of inventions can be used to apply a therapeutic monoclonal antibody in combination with an antibody-dependent cellular cytotoxicity (ADCC) molecule to increase ADCC. The ADCC strengthening molecule is {2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide. A combination and a kit for antibody-dependent cellular cytotoxicity increase is also proposed.
EFFECT: increased therapeutic activity of monoclonal antibodies.
14 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAHYDROFOLATES IN COMBINATION WITH EGFR INHIBITORS | 2013 |
|
RU2619335C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMPOSITIONS OF RECOMBINANT ANTIBODIES FROM EPIDERMAL GROWTH FACTOR RECEPTOR | 2009 |
|
RU2540146C2 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
